• Research: Boosting Subdominant Cancer-Specific T Cells

    December 12, 2017
    Dr. Mansour Haeryfar and his team at Schulich Medicine & Dentistry have uncovered a new mechanism underlying the beneficial effects of PD-1-based “checkpoint inhibitor”, therapeutic agents that are approved for the treatment of several types of cancer and also under investigation in clinical trials for numerus other types.